ClinicalTrials.gg
CompletedNCT04676724B-TogetherUpdated May 2, 2024Results posted

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

A Phase 2 interventional study of GSK3228836 and PegIFN in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 49 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-02.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · GlaxoSmithKline.

Enrollment
17th of 28
108 · median 163
Started
2021
the only one that year
Phase 2
5 of 30
none open now
Registered
24th of 30
by date

Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2021, is one of 5 in phase 2, and was the 24th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline is open now. Recruiting first, the newest first:

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants on stable nucleos(t)ide analogue (NA) therapy, and whether virologic response can be sustained once PegIFN treatment is discontinued. Participants will be randomized to receive GSK3228836 for 12 or 24 weeks followed by up to 24 weeks of PegIFN.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Chronic Hepatitis B
  • GSK3228836
  • Pegylated interferon
  • Nucleos(t)ide analogue
  • Sustained virologic response
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's enrollment of 108 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years of age at the time of signing the .
  • Participants who are eligible to be treated with PegIFN.
  • Documented chronic infection >=6 months prior to screening and currently receiving stable NA therapy except telbivudine, defined as no changes to their NA regimen from at least 6 months prior to screening and with no planned changes to the stable regimen over the duration of the study.
  • Plasma or serum HBsAg concentration >100 International Units per milliliter (IU/mL).
  • Plasma or serum HBV DNA concentration \<90 IU/mL.
  • \<=2 times .
  • A male participant is eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of study treatment: a) Refrain from donating sperm; b) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or agree to use /barrier: Agree to use a male condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak) when having sexual intercourse with a woman of who is not currently pregnant.
  • A female participant is eligible to participate: a) If she is not pregnant or breastfeeding; b) at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1 percent per year), preferably with low user dependency during the intervention period and for at least 90 days after the last dose of study treatment.
  • A WOCBP must have both a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative, a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • abnormalities, aside from chronic infection in medical history or physical examination.
  • Co-infection with: Current or past history of virus (HCV); (HIV); Hepatitis D virus (HDV).
  • History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by both: (AST)- Index (APRI) >2 and FibroSure/FibroTest result >0.7. If only one parameter (APRI or FibroSure/FibroTest) result is positive, a discussion with the Medical Monitor is required before inclusion in study is permitted. Regardless of APRI of Fibrosure/FibroTest score, if the participant meets one of the following criteria, they will be excluded from the study: a) Liver (i.e., Metavir Score F4); b) Liver stiffness >12 kilopascals (kPa).
  • Diagnosed or suspected hepatocellular carcinoma as evidenced by the following: Alpha- fetoprotein concentration >=200 nanogram per milliliter (ng/mL); If the screening alpha fetoprotein concentration is >=50 ng/mL and \<200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization.
  • History of within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
  • History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause) or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
  • History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
  • Poorly controlled thyroid dysfunction or abnormal thyroid stimulating hormone (TSH) levels
  • Positive (or borderline positive) anti-neutrophil cytoplasmic antibody (ANCA) at screening. Participants that meet these criteria may be considered for inclusion in the study following: a) Analysis of myeloperoxidase (MPO)-ANCA [perinuclear ANCA (pANCA)] and PR3-ANCA [classical ANCA (cANCA)]; b) A discussion with the Medical Monitor to review participant's complete medical history to ensure no past history or current manifestations of a vasculitic/inflammatory/auto-immune condition.
  • Low complement 3 (C3) at screening and evidence of past history or current manifestations of vasculitic/inflammatory/auto-immune conditions. All participants with low C3 at screening should have their medical history discussed with the Medical Monitor prior to enrolment.
  • History of alcohol or drug abuse/dependence. Current alcohol use as judged by investigator to potentially interfere with participant compliance; History of or current drug abuse/dependence as judged by the investigator to potentially interfere with participant compliance. Refers to illicit drugs and substances with abuse potential. Medications that are used by the participant as directed, whether over-the-counter or through prescription, are acceptable and would not meet the exclusion criteria.
  • Pre-existing severe psychiatric condition or a history of severe psychiatric disorders, including severe depression, suicidal ideation and attempted suicide.
  • Currently taking, or took within 3 months of screening, any drugs (e.g., prednisone), other than a short course of therapy (\<=2 weeks) or topical/inhaled use.
  • Participants for whom immunosuppressive treatment is not advised, including therapeutic doses of steroids, will be excluded.
  • Participants with prior treatment with PegINF or interferon will be excluded
  • Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors or anti-platelet agents like clopidogrel).
  • Participants currently taking, or took within 6 months of screening, telbivudine.
  • The participant has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 5 half-lives (if known) or twice the duration (if known) of the biological effect of the study treatment (whichever is longer) or 90 days (if half-life or duration is unknown).
  • Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA) within 12 months prior to the first dosing day.
  • Fridericia's correction formula (QTcF) >=450 milliseconds (msec) (if single [ECG] at screening shows QTcF>=450 msec, a mean of triplicate measurements should be used to confirm that participant meets exclusion criterion).
  • Laboratory results as follows: Serum albumin \<3.5 grams per deciliter (g/dL); (GFR) \<60 milliliter per minute per 1.73 square meter (mL/min /1.73 m\^2) as calculated by the Chronic Kidney Disease Epidemiologic Collaboration (CKD-EPI) formula (for Japan, Japanese Society of Nephrology Chronic Kidney Disease Initiative [JSN-CKDI equation]); (INR) >1.25; Platelet count \<140x10\^9 cells/L; Baseline \<10 g/dL; Total >1.25 times (For participants with benign unconjugated hyperbilirubinemia with total bilirubin >1.25 times ULN, discussion for inclusion to the study is required with the Medical Monitor); Urine albumin to creatinine ratio (ACR) >=0.03 milligram (mg)/mg (or >=30 mg/g). In the event of an ACR above this threshold, eligibility may be confirmed by a second measurement. In cases where participants have low urine albumin and low urine creatinine levels resulting in a urine ACR calculation >=0.03 mg/mg (or >=30 mg/g), the investigator should confirm that the participant does not have a history of diabetes, hypertension or other risk factors that may affect renal function and discuss with the Medical Monitor, or designee.
  • History of/sensitivity to GSK3228836 or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks)

    Participants on stable NA therapy received 300 milligrams per week (mg/week) GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by Pegylated Interferon (PegIFN) 180 microgram per week (mcg/week) up to 24 weeks.

    Drug: GSK3228836 · Drug: PegIFN · Drug: NA therapy

  • Experimental
    GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks)

    Participants on stable NA therapy received 300mg/week GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 mcg/week up to 24 weeks.

    Drug: GSK3228836 · Drug: PegIFN · Drug: NA therapy

Interventions

  • Participants will be administered GSK3228836.

  • DrugPegIFN

    Participants will be administered PegIFN.

  • DrugNA therapy

    Participants will continue to receive their NA therapy for the duration of the study.

07

What researchers measure

Primary outcomes

  1. Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment

    Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.

    Time frame: Up to 24 weeks off treatment (Study Weeks 48 to 72)

  2. Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment

    Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.

    Time frame: Up to 24 weeks off treatment (Study Weeks 36 to 60)

Secondary outcomes

  1. Treatment Arm 1: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)

    Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.

    Time frame: End of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  2. Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)

    Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.

    Time frame: End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  3. Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values

    Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.

    Time frame: Baseline, End of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  4. Treatment Arm 2: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values

    Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.

    Time frame: Baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  5. Treatment Arm 1: Number of Participants With Alanine Aminotransferase (ALT) Normalization

    The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.

    Time frame: At baseline, end of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  6. Treatment Arm 2: Number of Participants With Alanine Aminotransferase (ALT) Normalization

    The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.

    Time frame: At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  7. Treatment Arm 1: Number of Participants With HBe Antibody (Anti-HBeAg) Levels

    Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  8. Treatment Arm 2: Number of Participants With HBe Antibody (Anti-HBeAg) Levels

    Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.

    Time frame: At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  9. Treatment Arm 1: Mean Change From Baseline in HBe Antibody Levels

    Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  10. Treatment Arm 2: Mean Change From Baseline in HBe Antibody Levels

    Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  11. Treatment Arm 1: Actual Values of HBsAg Levels

    Blood samples were collected from participants to assess HBsAg at indicated time points.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  12. Treatment Arm 2: Actual Values of HBsAg Levels

    Blood samples were collected from participants to assess HBsAg at indicated time points.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  13. Treatment Arm 1: Mean Change From Baseline in HBsAg Levels

    Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  14. Treatment Arm 2: Mean Change From Baseline in HBsAg Levels

    Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  15. Treatment Arm 1: Actual Values of HBV DNA Levels

    Blood samples were collected to assess HBV DNA levels.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  16. Treatment Arm 2: Actual Values of HBV DNA Levels

    Blood samples were collected to assess HBV DNA levels.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  17. Treatment Arm 1: Mean Change From Baseline in HBV DNA Levels

    Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  18. Treatment Arm 2: Mean Change From Baseline in HBV DNA Levels

    Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  19. Treatment Arm 1: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels

    Blood samples were collected to assess HBeAg levels.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  20. Treatment Arm 2: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels

    Blood samples were collected to assess HBeAg levels.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  21. Treatment Arm 1: Mean Change From Baseline in HBeAg Levels

    Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  22. Treatment Arm 2: Mean Change From Baseline in HBeAg Levels

    Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  23. Treatment Arm 1: Actual Values of HBs Antibody Levels

    Blood samples were collected to assess HBs antibody levels.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  24. Treatment Arm 2: Actual Values of HBs Antibody Levels

    Blood samples were collected to assess HBs antibody levels.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  25. Treatment Arm 1: Mean Change From Baseline in HBs Antibody Levels

    Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  26. Treatment Arm 2: Mean Change From Baseline in HBs Antibody Levels

    Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  27. Treatment Arm 1: Actual Values of ALT

    Blood samples were collected to assess ALT mean values.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  28. Treatment Arm 2: Actual Values of ALT

    Blood samples were collected to assess ALT mean values.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  29. Treatment Arm 1: Change From Baseline in ALT

    Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

  30. Treatment Arm 2: Change From Baseline in ALT

    Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

  31. Treatment Arm 1 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment

    Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.

    Time frame: Up to 24 weeks off treatment (Study Week 48 to72)

  32. Treatment Arm 2 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment

    Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.

    Time frame: Up to 24 weeks off treatment (Study Weeks 36 to 60)

  33. Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks Off Treatment for Comparison of Efficacy Between Different Treatment Durations

    Sustained virologic response is defined as undetectable levels of HBsAg and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication. The point estimate for the difference in SVR and its respective credible interval (CI) were evaluated at 24 weeks off of planned treatment for both arms. The comparison of efficacy is between treatment durations and timepoint corresponds to Week 72 in Arm 1 and Week 60 in Arm 2. 95% CI here refers as credible interval. Percentage values are rounded-off.

    Time frame: Up to 24 weeks off treatment (Treatment Arm 1: Study Weeks 48 to 72 and Treatment Arm 2: Study Weeks 36 to 60)

08

Results

Posted May 2, 2024

Participant flow

A total of 108 participants were enrolled in this study.

Participant flow — Overall Study
MilestoneGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
Started5553
Completed4950
Not completed63
Withdrew: Adverse event20
Withdrew: Lost to follow-up10
Withdrew: Physician decision01
Withdrew: Withdrawal by subject32

Outcome measures

PrimaryTreatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment

Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.

Time frame:
Up to 24 weeks off treatment (Study Weeks 48 to 72)
Reported as:
Number · Percentage of Participants
Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment
Percentage of ParticipantsGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment9
PrimaryTreatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment

Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.

Time frame:
Up to 24 weeks off treatment (Study Weeks 36 to 60)
Reported as:
Number · Percentage of Participants
Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment
Percentage of ParticipantsGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment15
SecondaryTreatment Arm 1: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)

Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.

Time frame:
End of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Number · Percentage of Participants
Treatment Arm 1: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)
Percentage of ParticipantsGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
End of treatment (up to 48 weeks)15
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)13
SecondaryTreatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)

Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.

Time frame:
End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Number · Percentage of Participants
Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)
Percentage of ParticipantsGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
End of treatment (up to 36 weeks)15
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)17
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)15
SecondaryTreatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values

Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.

Time frame:
Baseline, End of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Number · Percentage of Participants
Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values
Percentage of ParticipantsGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
HBsAg <LLOQ - End of Treatment (up to 48 weeks)18
HBsAg<LLOQ - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)13
HBsAg decline <0.5 - End of Treatment (up to 48 weeks)24
HBsAg decline <0.5- Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)45
HBsAg decline >=0.5 - End of Treatment (up to 48 weeks)42
HBsAg decline >=0.5 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)44
HBsAg decline >=1 - End of Treatment (up to 48 weeks)33
HBsAg decline >=1- Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)36
HBsAg decline >=1.5 - End of Treatment (up to 48 weeks)27
HBsAg decline >=1.5 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)36
HBsAg decline >=3 - End of Treatment (up to 48 weeks)20
HBsAg decline >=3 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)27
SecondaryTreatment Arm 2: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values

Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.

Time frame:
Baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Number · Percentage of Participants
Treatment Arm 2: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values
Percentage of ParticipantsGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
HBsAg <LLOQ - End of Treatment (up to 36 weeks)15
HBsAg<LLOQ - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)17
HBsAg <LLOQ - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)15
HBsAg decline <0.5 - End of Treatment (up to 36 weeks)26
HBsAg decline <0.5 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)42
HBsAg decline <0.5 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)43
HBsAg decline >=0.5 - End of Treatment (up to 36 weeks)42
HBsAg decline >=0.5 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)51
HBsAg decline >=0.5 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)47
HBsAg decline >=1 - End of Treatment (up to 36 weeks)34
HBsAg decline >=1 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)34
HBsAg decline >=1 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)32
HBsAg decline >=1.5 - End of Treatment (up to 36 weeks)28
HBsAg decline >=1.5 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)23
HBsAg decline >=1.5-up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)19
HBsAg decline >=3 - End of Treatment (up to 36 weeks)15
HBsAg decline >=3 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)17
HBsAg decline >=3 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)17
SecondaryTreatment Arm 1: Number of Participants With Alanine Aminotransferase (ALT) Normalization

The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.

Time frame:
At baseline, end of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Count of participants · Participants
Treatment Arm 1: Number of Participants With Alanine Aminotransferase (ALT) Normalization
ParticipantsGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
ALT>ULN, At Baseline4
ALT normalization, End of Treatment (up to 48 weeks)0
ALT normalization, Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)2
SecondaryTreatment Arm 2: Number of Participants With Alanine Aminotransferase (ALT) Normalization

The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.

Time frame:
At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Count of participants · Participants
Treatment Arm 2: Number of Participants With Alanine Aminotransferase (ALT) Normalization
ParticipantsGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
ALT>ULN, At Baseline10
ALT normalization, End of Treatment (up to 36 weeks)1
ALT normalization, Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)5
ALT normalization, Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)6
SecondaryTreatment Arm 1: Number of Participants With HBe Antibody (Anti-HBeAg) Levels

Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Count of participants · Participants
Treatment Arm 1: Number of Participants With HBe Antibody (Anti-HBeAg) Levels
ParticipantsGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline2
End of Treatment (up to 48 weeks)5
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)4
SecondaryTreatment Arm 2: Number of Participants With HBe Antibody (Anti-HBeAg) Levels

Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.

Time frame:
At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Count of participants · Participants
Treatment Arm 2: Number of Participants With HBe Antibody (Anti-HBeAg) Levels
ParticipantsGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline1
End of Treatment (up to 36 weeks)1
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)1
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)0
SecondaryTreatment Arm 1: Mean Change From Baseline in HBe Antibody Levels

Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 1: Mean Change From Baseline in HBe Antibody Levels
Log10 IU/mLGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 48 weeks)-1.04 ± 1.133
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)-0.81 ± 1.044
SecondaryTreatment Arm 2: Mean Change From Baseline in HBe Antibody Levels

Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 2: Mean Change From Baseline in HBe Antibody Levels
Log10 IU/mLGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 36 weeks)-0.52 ± 0.598
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)-0.58 ± 0.766
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)-0.65 ± 0.787
SecondaryTreatment Arm 1: Actual Values of HBsAg Levels

Blood samples were collected from participants to assess HBsAg at indicated time points.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 1: Actual Values of HBsAg Levels
Log10 IU/mLGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline3.34 ± 0.555
End of Treatment (up to 48 weeks)1.52 ± 2.071
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)1.72 ± 2.043
SecondaryTreatment Arm 2: Actual Values of HBsAg Levels

Blood samples were collected from participants to assess HBsAg at indicated time points.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 2: Actual Values of HBsAg Levels
Log10 IU/mLGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline3.32 ± 0.622
End of Treatment (up to 36 weeks)1.70 ± 1.896
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)2.12 ± 1.827
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)2.12 ± 1.830
SecondaryTreatment Arm 1: Mean Change From Baseline in HBsAg Levels

Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 1: Mean Change From Baseline in HBsAg Levels
Log10 IU/mLGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 48 weeks)-1.76 ± 1.726
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)-1.58 ± 1.722
SecondaryTreatment Arm 2: Mean Change From Baseline in HBsAg Levels

Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 2: Mean Change From Baseline in HBsAg Levels
Log10 IU/mLGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 36 weeks)-1.54 ± 1.567
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)-1.20 ± 1.458
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)-1.20 ± 1.460
SecondaryTreatment Arm 1: Actual Values of HBV DNA Levels

Blood samples were collected to assess HBV DNA levels.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 1: Actual Values of HBV DNA Levels
Log10 IU/mLGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline0.64 ± 0.796
End of Treatment (up to 48 weeks)0.97 ± 0.629
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)0.17 ± 0.438
SecondaryTreatment Arm 2: Actual Values of HBV DNA Levels

Blood samples were collected to assess HBV DNA levels.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 2: Actual Values of HBV DNA Levels
Log10 IU/mLGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline0.57 ± 0.687
End of treatment (up to 36 weeks)0.70 ± 0.700
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)0.34 ± 0.579
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)0.35 ± 0.587
SecondaryTreatment Arm 1: Mean Change From Baseline in HBV DNA Levels

Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 1: Mean Change From Baseline in HBV DNA Levels
Log10 IU/mLGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
End of treatment (up to 48 weeks)0.40 ± 0.945
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)-0.39 ± 0.727
SecondaryTreatment Arm 2: Mean Change From Baseline in HBV DNA Levels

Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 2: Mean Change From Baseline in HBV DNA Levels
Log10 IU/mLGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 36 weeks)0.21 ± 0.925
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)-0.21 ± 0.876
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)-0.22 ± 0.754
SecondaryTreatment Arm 1: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels

Blood samples were collected to assess HBeAg levels.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 1: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels
Log10 IU/mLGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline14.221 ± 69.3438
End of Treatment (up to 48 weeks)0.250 ± 0.4193
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)1.197 ± 2.4945
SecondaryTreatment Arm 2: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels

Blood samples were collected to assess HBeAg levels.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 2: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels
Log10 IU/mLGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline8.510 ± 42.1588
End of Treatment (up to 36 weeks)3.008 ± 6.2682
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)3.410 ± 6.0421
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)2.797 ± 4.8973
SecondaryTreatment Arm 1: Mean Change From Baseline in HBeAg Levels

Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 1: Mean Change From Baseline in HBeAg Levels
Log10 IU/mLGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 48 weeks)-21.774 ± 65.4276
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)-19.482 ± 55.1948
SecondaryTreatment Arm 2: Mean Change From Baseline in HBeAg Levels

Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/mL
Treatment Arm 2: Mean Change From Baseline in HBeAg Levels
Log10 IU/mLGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 36 weeks)-5.270 ± 8.8942
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)-26.384 ± 80.2108
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)-26.345 ± 77.2836
SecondaryTreatment Arm 1: Actual Values of HBs Antibody Levels

Blood samples were collected to assess HBs antibody levels.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/L
Treatment Arm 1: Actual Values of HBs Antibody Levels
Log10 IU/LGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline0.62 ± 0.271
End of Treatment (up to 48 weeks)1.06 ± 0.903
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)0.82 ± 0.718
SecondaryTreatment Arm 2: Actual Values of HBs Antibody Levels

Blood samples were collected to assess HBs antibody levels.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/L
Treatment Arm 2: Actual Values of HBs Antibody Levels
Log10 IU/LGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline0.69 ± 0.204
End of Treatment (up to 36 weeks)0.87 ± 0.491
Up to 24 weeks off treatment follow-up (study week 36 to week 60)0.80 ± 0.521
Up to 36 weeks off treatment follow-up (study week 36 to week 72)0.76 ± 0.481
SecondaryTreatment Arm 1: Mean Change From Baseline in HBs Antibody Levels

Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · Log10 IU/L
Treatment Arm 1: Mean Change From Baseline in HBs Antibody Levels
Log10 IU/LGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
End of treatment (up to 48 weeks)0.42 ± 0.934
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)0.18 ± 0.757
SecondaryTreatment Arm 2: Mean Change From Baseline in HBs Antibody Levels

Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · Log10 IU/L
Treatment Arm 2: Mean Change From Baseline in HBs Antibody Levels
Log10 IU/LGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 36 weeks)0.18 ± 0.450
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)0.09 ± 0.487
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)0.05 ± 0.453
SecondaryTreatment Arm 1: Actual Values of ALT

Blood samples were collected to assess ALT mean values.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · International Units Per Liter (IU/L)
Treatment Arm 1: Actual Values of ALT
International Units Per Liter (IU/L)GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline22.7 ± 13.97
End of Treatment (up to 48 weeks)53.1 ± 60.61
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)19.2 ± 9.77
SecondaryTreatment Arm 2: Actual Values of ALT

Blood samples were collected to assess ALT mean values.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · IU/L
Treatment Arm 2: Actual Values of ALT
IU/LGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
At Baseline26.9 ± 19.16
End of Treatment (up to 36 weeks)55.3 ± 46.60
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)22.1 ± 13.30
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)23.5 ± 15.61
SecondaryTreatment Arm 1: Change From Baseline in ALT

Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Reported as:
Mean · IU/L
Treatment Arm 1: Change From Baseline in ALT
IU/LGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
End of Treatment (up to 48 weeks)27.6 ± 56.05
Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)-3.8 ± 9.86
SecondaryTreatment Arm 2: Change From Baseline in ALT

Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Reported as:
Mean · IU/L
Treatment Arm 2: Change From Baseline in ALT
IU/LGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
End of treatment (up to 36 weeks)27.8 ± 40.55
Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60)-4.3 ± 17.50
Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)-3.1 ± 18.65
SecondaryTreatment Arm 1 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment

Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.

Time frame:
Up to 24 weeks off treatment (Study Week 48 to72)
Reported as:
Median · Weeks
Treatment Arm 1 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment
WeeksGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)
Treatment Arm 1 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of TreatmentNA (6.3 to NA)
SecondaryTreatment Arm 2 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment

Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.

Time frame:
Up to 24 weeks off treatment (Study Weeks 36 to 60)
Reported as:
Median · Weeks
Treatment Arm 2 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment
WeeksGSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
Treatment Arm 2 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment4.1 (1.1 to 47.1)
SecondaryPercentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks Off Treatment for Comparison of Efficacy Between Different Treatment Durations

Sustained virologic response is defined as undetectable levels of HBsAg and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication. The point estimate for the difference in SVR and its respective credible interval (CI) were evaluated at 24 weeks off of planned treatment for both arms. The comparison of efficacy is between treatment durations and timepoint corresponds to Week 72 in Arm 1 and Week 60 in Arm 2. 95% CI here refers as credible interval. Percentage values are rounded-off.

Time frame:
Up to 24 weeks off treatment (Treatment Arm 1: Study Weeks 48 to 72 and Treatment Arm 2: Study Weeks 36 to 60)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks Off Treatment for Comparison of Efficacy Between Different Treatment Durations
Percentage of participantsGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks Off Treatment for Comparison of Efficacy Between Different Treatment Durations915
Statistical analysis
  • GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) vs GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) · Difference in svr rate: -3 · 95% CI -29 to 11The point estimate of SVR and its 95% highest posterior density Credible Interval (CI) are estimated from a Bayesian model that incorporates the analysis stratification factors and treatment arm.

Adverse events

Collected over Up to Week 72. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)0/55 (0%)6/55 (10.9%)52/55 (94.5%)
GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)0/53 (0%)2/53 (3.8%)50/53 (94.3%)
Most frequent serious events
Most frequent serious events
EventGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
Peritonsillar abscessInfections and infestations0/551/53
Spinal stenosisMusculoskeletal and connective tissue disorders0/551/53
CholecystitisHepatobiliary disorders1/550/53
CholelithiasisHepatobiliary disorders1/550/53
Drug-induced liver injuryHepatobiliary disorders1/550/53
AppendicitisInfections and infestations1/550/53
COVID-19Infections and infestations1/550/53
Chest injuryInjury, poisoning and procedural complications1/550/53
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/550/53
Most frequent other events
Showing 10 of 228
Most frequent other events
EventGSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)
Alanine aminotransferase increasedInvestigations23/556/53
Injection site erythemaGeneral disorders20/5522/53
PyrexiaGeneral disorders17/5514/53
Aspartate aminotransferase increasedInvestigations16/556/53
COVID-19Infections and infestations15/555/53
ThrombocytopeniaBlood and lymphatic system disorders14/5511/53
Neutrophil count decreasedInvestigations14/558/53
NeutropeniaBlood and lymphatic system disorders10/5512/53
MyalgiaMusculoskeletal and connective tissue disorders6/5512/53
HeadacheNervous system disorders7/5512/53

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)Total
Mean45.5 ± 10.7345.5 ± 9.3545.5 ± 10.03
Sex: Female, Male
Sex: Female, Male(Participants)GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)Total
Female112031
Male443377
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks)GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks)Total
ASIAN302656
BLACK OR AFRICAN AMERICAN336
WHITE222446
09

Study locations

49 sites
  • GSK Investigational Site
    Sacramento, California 95817, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
  • GSK Investigational Site
    Edmonton, Alberta T6G 2X8, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Changchun, Jilin 130021, China
  • GSK Investigational Site
    Beijing, 100015, China
  • GSK Investigational Site
    Beijing, 100069, China
  • GSK Investigational Site
    Hangzhou, 310000, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Baggiovara (MO), Emilia-Romagna 40126, Italy
  • GSK Investigational Site
    Milano, Lombardia 20122, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Monza (MB), Lombardia 20900, Italy
  • GSK Investigational Site
    Aichi, 467-8602, Japan
  • GSK Investigational Site
    Fukui, 918-8503, Japan
  • GSK Investigational Site
    Gifu, 500-8717, Japan
  • GSK Investigational Site
    Hiroshima, 737-0023, Japan
  • GSK Investigational Site
    Kumamoto, 860-8556, Japan
  • GSK Investigational Site
    Nagasaki, 856-8562, Japan
  • GSK Investigational Site
    Tokyo, 113-8603, Japan
  • GSK Investigational Site
    Busan, 49241, Korea, Republic of
  • GSK Investigational Site
    Daegu, 41944, Korea, Republic of
  • GSK Investigational Site
    Gyeonggi-do, 15355, Korea, Republic of
  • GSK Investigational Site
    Gyeonggi-do, 463-712, Korea, Republic of
  • GSK Investigational Site
    Ulsan, 44033, Korea, Republic of
  • GSK Investigational Site
    Lancut, 37-100, Poland
  • GSK Investigational Site
    Lublin, 20-884, Poland
  • GSK Investigational Site
    Myslowice, 41-400, Poland
  • GSK Investigational Site
    Barnaul, 656010, Russian Federation
  • GSK Investigational Site
    Chelyabinsk, 454052, Russian Federation
  • GSK Investigational Site
    Krasnojarsk, 660049, Russian Federation
  • GSK Investigational Site
    Moscow, 121170, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630099, Russian Federation
  • GSK Investigational Site
    Samara, 443063, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 190103, Russian Federation
  • GSK Investigational Site
    Ennerdale, Gauteng 1830, South Africa
  • GSK Investigational Site
    Johannesburg, Gauteng 1401, South Africa
  • GSK Investigational Site
    Barcelona, 08011, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28031, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    London, WC1E 6JB, United Kingdom
  • GSK Investigational Site
    Newcastle-upon-Tyne, NE7 7DN, United Kingdom
  • GSK Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • GSK Investigational Site
    Plymouth, PL68DH, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Feb 2023, 24 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 24 months is close to that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2020
First posted
Dec 21, 2020
StartActual
Jan 28, 2021
Primary completionActual
Feb 17, 2023
CompletionActual
Feb 17, 2023
Results first posted
May 2, 2024
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04676724
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Jan 28, 2021
Primary completion
Feb 17, 2023
Completion
Feb 17, 2023
Results posted
May 2, 2024
Last update
May 2, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion